Welcome to our dedicated page for Editas Medicine SEC filings (Ticker: EDIT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Editas Medicine, Inc. (Nasdaq: EDIT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a clinical-stage gene editing company focused on in vivo CRISPR/Cas12a and CRISPR/Cas9 medicines, Editas uses current reports on Form 8-K and other periodic filings to communicate material events, program updates, collaborations, and financial results to investors.
Through its 8-K filings, Editas Medicine furnishes press releases announcing quarterly financial results, cash runway expectations, and business highlights. These documents describe research and development expenses, collaboration and other research revenues, restructuring and impairment charges, and the company’s view of its ability to fund operating expenses and capital expenditure requirements over a multi-year period. They also outline key risk considerations and refer readers to the company’s Annual Report on Form 10-K and subsequent filings for detailed risk factors.
Filings also summarize important scientific and pipeline milestones. For example, Editas has used 8-K reports to describe the nomination of EDIT-401 as its lead in vivo development candidate for hyperlipidemia, preclinical proof-of-concept data demonstrating approximately 90% LDL-C reduction in non-human primates and mice, and the therapeutic strategy of using CRISPR/Cas9 with dual guide RNAs and lipid nanoparticle delivery to upregulate LDLR. Other filings discuss in vivo proof-of-concept data for EDIT-401 presented at major gene and cell therapy conferences.
Investors can review these SEC filings to understand how Editas Medicine reports the status of its in vivo HSC program for sickle cell disease and beta thalassemia, its collaboration with Bristol Myers Squibb on T cell medicines, and payments under its license agreement with Vertex Pharmaceuticals. On Stock Titan, AI-powered tools can help summarize lengthy filings, highlight key sections related to EDIT-401, cash runway, collaborations, and program changes, and make it easier to interpret complex technical and financial disclosures without reading every line of each document.
Editas Medicine insider transaction by SVP & Chief Financial Officer Amy Parison: The filing reports a non-discretionary sale of 679 shares of common stock at $2.58 per share, executed under a durable automatic sales instruction plan. The sale satisfied tax withholding obligations arising from the vesting of restricted stock units and is explicitly described as not a discretionary trade by the reporting person.
After the reported sale the reporting person beneficially owned 16,827 shares directly. The filing identifies the issuer as Editas Medicine, Inc. and classifies the report as a Form 4 statement of changes in beneficial ownership.